This article was originally published in The Rose Sheet
The termination of certain employees and other actions under initiatives to outsource certain services per the firm's ongoing multi-year restructuring initiative will result in charges of about $5 mil.-$6 mil. before taxes, direct seller states in an Oct. 17 Securities and Exchange Commission filing. Charges of $4.4 mil. will be recorded in Q3 2006, firm says, adding the employee cuts will be completed by 2009. Avon announced its restructuring plan last fall, noting it will result in costs of $300 mil.-$500 mil. before taxes (1"The Rose Sheet" Nov. 21, 2005, p. 3)...
You may also be interested in...
Avon will launch several new skin care and color cosmetics initiatives next year and significantly increase advertising investment in an effort to restore competitiveness and drive revenue growth, according to CEO Andrea Jung
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.